Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Faron Pharmaceuticals Oy

https://www.faron.com/

Latest From Faron Pharmaceuticals Oy

For COVID, Consensus On Value Of Platform Trials, But A Confusion Of Consortia

The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.

Coronavirus COVID-19 Clinical Trials

COVID-19 Phase III Trial Design: Big Ambitions, Little Consistency

As remdesivir’s change in primary endpoint illustrates, there are many ways to measure potential treatments. A Pink Sheet analysis of 50 Phase III clinical trial protocols found numerous different approaches. Adaptive trials seems critical for speed, but a survival endpoint seems essential for durability.

Clinical Trials Coronavirus COVID-19

Coronavirus Update: Funding Projects, New Clinical Trials, & Cannabis

In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.

International Europe

Coronavirus Update: $7.8bn Goal To Create Global COVID-19 Strategy

World Health Organization brings together global leaders and NGOs - but US and China's absence raises fears of national response to vaccine.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Faron Ventures, Ltd., Faron Pharmaceuticals, Ltd.
UsernamePublicRestriction

Register